In addition a high frequency of immune ABO
In addition, a high frequency of immune ABO GSK503 (69%) has been reported in group O Thai blood donors. Moreover, a high frequency of IgG anti-A and anti-B hemolysins was reported in Asian and African-American populations, relative to that in Caucasians. This discrepancy might also explain the higher rate of false-positivity in the present Taiwanese cohort. However, data from a blood transplant donor population indicated that only 13% had high anti-A or -B Ab titers (>100). This finding might explain why false-positive anti-ICS IIF test results were not obtained for all patients with blood type O.
Introduction Psoriasis is a chronic, noncontagious skin disease with a wide range of prevalences in different ethnic groups. Previous studies have shown a prevalence rate of 0.226% among Taiwanese people, as well as a male to female ratio of 2:1. On average, females have a younger age of onset, while 20% of patients have a family history of the disease. Although psoriasis is rarely life threatening, it results in a poor quality of life (QOL), with an impact comparable with that of diabetes. In addition to suffering from the physiological effects of the illness, psoriasis patients have to face psychological issues such as frustration, helplessness, and lack of self-confidence because of changes in the appearance of their skin. A good correlation between the severity of psoriasis, measured by the Psoriasis Area and Severity Index (PASI), and QOL was previously demonstrated in many pivotal studies investigating Caucasian patients with moderate to severe psoriasis. At present, the study instruments used to measure patients\' subjective QOL indexes include generic instruments short form-36 (SF-36), specific instruments, health state utilities, and contingency valuation methods. The Dermatology Life Quality Index (DLQI) and the SF-36 are the most frequently used measures. In fact, the recent argument that higher treatment efficacy of PASI90 (rather than PASI75) should be sought for psoriasis in the era of biologics is based on DLQI statistics. Similarly, our own previous study regarding unreimbursed use of adalimumab for psoriasis also found a DLQI score of 0–1 to be a critical factor. Other measures of health state utilities are used relatively infrequently. As the various domains of the different generic and specific instruments will generate different values, the use of a multidimensional approach in describing the overall health-related QOL has advantages in terms of better reflecting a patient\'s health condition across multiple domains. In addition, studies showing correlations among these measurements in milder psoriasis are limited, and their correlations, if any, among Asian patients with psoriasis have yet to be investigated. There have only been a limited number of studies Exocytosis focused on the correlations between preference-based scales and health profile-based scales. For example, Lundberg et al compared the relationships among health state utilities, willingness to pay (WTP), and QOL scales for 366 patients with psoriasis and atopic eczema, but that study did not take disease severity into account, and there has been, to our knowledge, no previous study conducted in Asia that has compared the relationships among the DLQI, health state utilities, and WTP. In a small case series involving 40 patients, WTP was not correlated with the severity of psoriasis (as measured by the body surface area involved). In the current study, we examined how different measures of health state utilities and WTP are related to the DLQI, and how their correlations vary over differing levels of PASI scores, among Taiwanese patients with psoriasis.
Results Characteristics of the patients are shown in Table 1. There were 360 (75.0%) male patients and 120 (25.0%) female patients, and their average age was 44.52 years. The average disease duration was 10.9 years. In terms of disease severity, 117 (24.4%) respondents had mild psoriasis (PASI < 3), 208 (43.3%) had moderate psoriasis (3 ≤ PASI < 10), and 155 (32.3%) had severe psoriasis (PASI ≥ 10).